Drug news
Qnexa to be re-filed at FDA for Obesity
Vivus will resubmit its application to the FDA for Qnexa (phentermine plus topiramate), by the end of October,which is about two months before top-line results are expected from the firm's retrospective observational study assessing fetal outcomes in the offspring of women exposed to topiramate(forming part of Qnexa) during the first trimester of pregnancy. Results of the study are expected by the third quarter of 2012.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins